Compare HPQ & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HPQ | WAT |
|---|---|---|
| Founded | 1939 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9B | 22.5B |
| IPO Year | N/A | 1995 |
| Metric | HPQ | WAT |
|---|---|---|
| Price | $23.20 | $374.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 15 |
| Target Price | $25.85 | ★ $390.67 |
| AVG Volume (30 Days) | ★ 14.2M | 559.4K |
| Earning Date | 11-25-2025 | 11-04-2025 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | N/A | ★ 3.82 |
| EPS | 2.65 | ★ 10.88 |
| Revenue | ★ $55,295,000,000.00 | $3,105,638,000.00 |
| Revenue This Year | $2.73 | $7.96 |
| Revenue Next Year | $1.39 | $6.32 |
| P/E Ratio | ★ $8.85 | $34.60 |
| Revenue Growth | 3.24 | ★ 6.90 |
| 52 Week Low | $21.21 | $275.05 |
| 52 Week High | $35.28 | $423.56 |
| Indicator | HPQ | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 35.13 | 43.63 |
| Support Level | $22.98 | $372.93 |
| Resistance Level | $25.58 | $397.55 |
| Average True Range (ATR) | 0.67 | 9.27 |
| MACD | -0.11 | -4.08 |
| Stochastic Oscillator | 6.37 | 11.63 |
HP (formerly Hewlett-Packard) is a behemoth in the PC and printing markets. It has focused on these markets since it exited IT infrastructure in 2015 with the split from Hewlett Packard Enterprise. HP focuses on the commercial market, but maintains sales of consumer devices and printers. The firm has a broad and global customer base, with only one third of sales coming from the US. HP completely outsources manufacturing and relies heavily on channel partners for its sales and marketing.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.